This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Transvaginal Mesh Lawsuit Update: Plaintiff's Closing Argument Stresses Proof That J&J Ignored Info About Prolift's Dangers, Rottenstein Law Group Reports

ATLANTIC CITY, N.J., Feb. 16, 2013 /PRNewswire/ -- As part of the closing arguments he delivered at the trial of a vaginal mesh lawsuit in New Jersey Superior Court today, the attorneys for plaintiff Linda Gross, 47, showed the jury e-mails and re-played videotaped deposition testimony showing Ethicon's repeated decisions to ignore reports of complications related to its Prolift vaginal mesh in a rush to get that mesh to market, the Rottenstein Law Group reports.

(Photo:  http://photos.prnewswire.com/prnh/20130216/NY61533)

Gross' attorney illustrated that executives at medical device manufacturer Ethicon repeatedly ignored the concerns of at least one doctor about the safety of the company's Prolift vaginal mesh kit by showing the jury copies of the executives' e-mails. In those e-mails, Ethicon executives stated that: (1) They respected the doctor's opinion; and (2) Should get back to the doctor in the interest of understanding his concerns. The executives nevertheless failed to follow up with the doctor properly, Gross' attorney said. This is the first of 1,800 vaginal mesh lawsuits against Ethicon pending in New Jersey Superior Court to go to trial.

Among the other evidence that Gross' attorney presented again to the jury during his closing argument was the testimony of Scott Ciarrocca, an Ethicon executive, which stated that Ethicon executives were motivated to get the Prolift to market as soon as possible in order to beat the launch of AMS mesh, a product created by one of Ethicon's competitors.

"We're relieved that one of the Prolift cases has gone to trial," said Rochelle Rottenstein, principal of the Rottenstein Law Group, which represents women in vaginal mesh lawsuits. "We look forward to helping other women who've been seriously harmed by vaginal mesh products get compensation for their injuries."

The Rottenstein Law Group maintains a website that describes all of the issues vaginal mesh patients face and explains their options. You may visit the website here. A free informational brochure about the process of preparing a lawsuit is available for download.

About the Rottenstein Law GroupThe Rottenstein Law Group is a New York-based law firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, a lawyer with over two decades of experience in compassionate representation of clients in consumer product injury, mass tort, and class action lawsuits. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:The Rottenstein Law Group, LLP Rochelle Rottenstein, Esq.321 W. 44th Street# 804 New York NY 10036(212) 933-9500 (office phone)(212) 933-9980 (facsimile)rochelle (at) rotlaw (dot) com www.rotlaw.com www.rotlaw.com/transvaginal-placement-of-surgical-mesh/

SOURCE The Rottenstein Law Group

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,195.42 +221.11 1.30%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,566.1380 +16.9120 0.37%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs